Available Until 11/21/2023

Pharmacotherapy Specialty Review Course for Recertification, Core Therapeutic Modules + RECERT EXAMS Package (Cert # L229273)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 10/26/2022
Content Release Date: 11/23/2022
Expiration Date: 11/21/2023
Activity Type: Application-based
CE Credits: 21 (BPS and ACPE) contact hours
Activity Fee: $475 (ASHP member); $675 (non-member)

Activity Overview

The Review Course activities are being recorded during a live educational event on December 3-4, 2022 at the Midyear Clinical Meeting in Las Vegas. Learners who claim credit for the live activities should not claim credit for these home study activities. Please note, the recordings and assessments will be available on 2/1/23.

This course is intended for BCPS's in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

  • Review pertinent clinical topics and practice skills
  • List valuable resources for further self-study  

This online course consists of 16 activities (see tables below) and provides up to 21 contact hours of continuing pharmacy education credit and/or recertification credit.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in pharmacotherapy.

Board certified pharmacists are eligible to receive up to 16 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Pharmacotherapy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/ptherapy-review 

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS.

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

Learning Activity

ACPE Number

Contact Hours

Cardiovascular Disease: Primary Prevention Case

0204-0000-22-605-H01-P

1.50 ACPE

Cardiovascular Disease: Secondary Prevention Case

0204-0000-22-606-H01-P

1.50 ACPE

Complex Heart Failure Case

0204-0000-22-607-H01-P

1.50 ACPE

Providing Safe and Effective Pharmacotherapy: Key Regulatory and Quality Approaches

0204-0000-22-608-H05-P

1.50 ACPE

  →   Recertification Assessment: Group 1 (tbd% passing score required)

6.0 BPS

Research Methods and Data Analysis

0204-0000-22-609-H04-P

1.50 ACPE

Evidence-based Practice and Resources

0204-0000-22-647-L04-P

1.0 ACPE

Oncology and Supportive Care Case

0204-0000-22-610-H01-P

1.50 ACPE

Complex Nursing Home Patient Case

0204-0000-22-611-H01-P

1.50 ACPE

  →   Recertification Assessment: Group 2  (tbd% passing score required)

5.5 BPS

Complex HIV/AIDS Case

0204-0000-22-612-H02-P

1.50 ACPE

Complex Pediatric Asthma Case

0204-0000-22-613-H01-P

1.75 ACPE

Complex Pneumonia Case

0204-0000-22-614-H01-P

1.25 ACPE

  →  Recertification Assessment: Group 3 (tbd% passing score required)

4.5 BPS

After participating in this CPE activity, learners should be able to:

Cardiovascular Disease: Primary Prevention Case
ACPE#: 0204-0000-22-605-H01-P

  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including hypertension, dyslipidemia, chronic kidney disease, diabetes, and obesity.
  • State the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommendations for adult immunizations.
  • Determine how to advise a patient on point-of-care testing to measure response to drug therapy.
  • Discuss national benchmarking standards and implications to patient care. 

Cardiovascular Disease: Secondary Prevention Case
ACPE#: 0204-0000-22-606-H01-P

  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including atrial fibrillation (AF), acute coronary syndromes (ACS), and gastroesophageal reflux disease (GERD).
  • Develop a plan to address continuity of care issues.
  • Formulate a medication therapy plan for smoking cessation.
  • Determine how to manage drug – drug and drug-induced disease interactions in a patient with ischemic heart disease.
  • Discuss quality of life in this population.
  • Discuss national benchmarking standards and implications to patient care. 

Complex Heart Failure Case
ACPE#: 0204-0000-22-607-H01-P

  • Select optimal treatment and monitoring for a complex patient-case with multiple conditions, including heart failure, electrolyte disturbances in acute decompensated heart failure, diabetes, and a thyroid disorder.
  • Discuss the medications that should be avoided in heart failure.
  • Identify safety issues in this population.
  • Define inadequate health literacy in this population. 

Providing Safe and Effective Pharmacotherapy:  Key Regulatory and Quality Approaches
ACPE#: 0204-0000-22-608-H05-P

  • Explain the regulatory and accreditation  requirements of a comprehensive medication use program.
  • Describe methods to develop and maintain a medication use system.
  • Discuss technology used to promote safe and effective medication use.
  • Apply national regulations and evidence-based practices for medication safety and quality.
  • Interpret results from pharmacotherapy-related quality improvement activities. 

Research Methods and Data Analysis
ACPE#: 0204-0000-22-609-H04-P

  • Analyze biomedical literature with regard to study methodology, statistical analysis, and significance.
  • Explain the use of evidence-based treatment guidelines and protocols.
  • Interpret the biomedical literature and its application to clinical practice. 

Evidence-based Practice and Resources
ACPE#: 0204-0000-22-647-L04-P

  • Identify sources of information to use to answer questions in one’s practice, or from patients and healthcare professionals.
  • Explain how to provide education regarding evidence-based practice to current and future health care professionals.

Oncology and Supportive Care Case
ACPE#: 0204-0000-22-610-H01-P

  • Select the appropriate treatment and monitoring of a complex patient-case with multiple conditions, including breast cancer, febrile neutropenia, and pulmonary embolism.
  • Compare and contrast current breast cancer screening recommendations.
  • Develop a plan to manage pain and nausea/vomiting in a patient with cancer.
  • Discuss safety issues in this population.
  • Discuss adherence issues with oral chemotherapy regimens. 

Complex Nursing Home Patient Case
ACPE#: 0204-0000-22-611-H01-P

  • Select the appropriate treatment for a complex patient-case with multiple conditions, including stroke, depression/anxiety, dementia, chronic obstructive pulmonary disease, osteoarthritis, osteoporosis, and pain.
  • Discuss complementary/alternative medicine and safety issues in older adults.
  • Discuss quality improvement initiatives and regulations in the nursing home setting. 

Complex HIV/AIDS Case
ACPE#: 0204-0000-22-612-H02-P

  • Select the appropriate treatment and monitoring of a complex patient-case with multiple conditions, including HIV infection, dyslipidemia, and hepatitis B.
  • Identify and manage common drug interactions experienced by HIV-treated patients.
  • Identify and manage common adverse drug reactions experienced by HIV-treated patients.
  • Determine appropriate medication choices for the treatment and prevention of common opportunistic infections.
  • Discuss quality of life issues in terms of medication therapy for HIV-infected patients.
  • Discuss recommendations for pre-exposure prophylaxis (PrEP). 

Complex Pediatric Asthma Case
ACPE#: 0204-0000-22-613-H01-P

  • Select optimal treatment and monitoring for a complex patient-case with acute asthma exacerbation, acute otitis media, and seasonal allergies.
  • Apply methods for counseling a patient and/or caregiver in asthma self-management with comprehensive documentation of the patient counseling.
  • Develop a plan for childhood vaccinations in a child who has been delayed in receiving them.
  • Implement principles of shared-decision making and culturally effective care when using complementary/alternative medicine in a pediatric patient. 

Complex Pneumonia Case
ACPE#: 0204-0000-22-614-H01-P

  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including pneumonia, acute renal insufficiency, sepsis, chronic obstructive pulmonary disease, and dehydration.
  • Interpret clinical data, including lab, physical examination and vital signs.
  • Determine and prioritize pneumonia-related treatment goals.
  • Determine approaches to manage drug allergies and select next best drug therapy when primary drugs are precluded.
  • Discuss approaches to limiting antimicrobial over use by stewarding antibiotic usage appropriately.
  • Discuss safety issues in patients receiving treatment for pneumonia.

The Core Therapeutic Modules Review Package consists of 5 activities in which faculty review clinical topics and practice skills using a case-based approach. The activities are designed to assist the learner in identifying knowledge gaps in preparation for a pharmacy specialty board examination. In addition to a recorded presentation, each activity includes links to resources for further self-study and a practice test developed in the same format and rigor as the specialty exam.

Learning Activity

ACPE Number

Contact Hours

Select Topics in Infectious Diseases: Part 1

0204-0000-22-615-H01-P

1.00 ACPE

Select Topics in Infectious Diseases: Part 2

0204-0000-22-616-H01-P

1.00 ACPE

Fluid, Electrolytes, and Nutrition

0204-0000-22-617-H01-P

1.00 ACPE

Select Topics in Neurologic Disorders

0204-0000-22-618-H01-P

1.00 ACPE

Diabetes

0204-0000-22-619-H01-P

1.00 ACPE

  →   Recertification Assessment: Core Therapeutic Modules 75% passing score required)

5.00 BPS

After participating in these CPE activities, learners should be able to:

Select Topics in Infectious Diseases: Part 1
ACPE#: 0204-0000-22-615-H01-P

For the following infectious diseases: c.difficile infection, skin and soft tissue infections, upper respiratory tract infections, community acquired pneumonia

  • Interpret laboratory and diagnostic tests.
  • Formulate the most appropriate treatment, monitoring, and follow-up plans based on patient-specific information and current guidelines.
  • Evaluate drug-related problems. 

Select Topics in Infectious Diseases: Part 2
ACPE#: 0204-0000-22-616-H01-P

For the following infectious diseases: sexually transmitted diseases, urinary tract infections, endocarditis, meningitis

  • Interpret laboratory and diagnostic tests.
  • Formulate the most appropriate treatment, monitoring, and follow-up plans based on patient-specific information and current guidelines.
  • Evaluate drug-related problems. 

Fluid, Electrolytes, and Nutrition
ACPE#: 0204-0000-22-617-H01-P

  • Interpret laboratory and diagnostic tests for fluid, electrolyte, and nutrition status.
  • Recommend the most appropriate therapy and monitoring in patients with fluid, electrolyte, and nutritional disorders based on patient-specific information and current guidelines.
  • Apply strategies to manage drug-related electrolyte interactions and nutrient interactions. 

Select Topics in Neurologic Disorders
ACPE#: 0204-0000-22-618-H01-P

For patients with seizure disorders, Parkinson’s disease, headache and sleep disorders:

  • Evaluate the risks and benefits of drug therapy considering other medication and patient specific factors.
  • Formulate the most appropriate treatment, monitoring and follow-up plans based on patient-specific information and current guidelines.
  • Evaluate drug-related problems. 

Diabetes
ACPE#: 0204-0000-22-619-H01-P

  • Interpret diagnostic and/or laboratory tests in patients with diabetes.
  • Formulate the most appropriate treatment, monitoring, and follow-up plans based on patient-specific information and current guidelines.
  • Evaluate drug-related problems.

Faculty bios

Christopher Betz, PharmD, BCPS, FKSHP, FASHP*
Associate Professor, Clinical and Administrative Sciences
Sullivan University College of Pharmacy
Louisville, Kentucky 

Snehal H. Bhatt, PharmD, BCPS-AQ Cardiology, FASHP, AACC*
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts 

Kalin Clifford, PharmD, BCPS, BCGP, FASCP
Associate Professor of Pharmacy Practice
Division of Geriatrics and Pediatrics
Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy
Advanced Practice Pharmacist/Clinical Pharmacy Specialist, Geriatrics & Extended Care
VA North Texas Health Care System
Dallas, Texas 

Lourdes Cross, PharmD, BCACP, CDCEs
Assistant Professor
Sullivan University College of Pharmacy & Health Sciences
Clinical Pharmacy Specialist
University of Louisville Hospital
Louisville, Kentucky
 

Stuart T. Haines, PharmD, BCPS, BCACP, FASHP
Professor and Director, Professional Development
University of Mississippi School of Pharmacy
Jackson, Mississippi 

Patricia C. Kienle, BSPharm, MPA, BCSCP, FASHP
Director, Accreditation and Medication Safety
Cardinal Health Innovative Delivery Systems
Wilkes-Barre, Pennsylvania 

Krutika Mediwala Hornback, PharmD, BCPS, BCIDP
Infectious Diseases/Antimicrobial Stewardship Clinical Pharmacy Specialist
Medical University of South Carolina (MUSC) Health
Infectious Diseases Pharmacy Residency Program Director
MUSC Health
Charleston, South Carolina 

Jill Morgan, PharmD, BCPS, BCPPS
Professor and Chair
University of Maryland School of Pharmacy
Baltimore, Maryland 

Victoria R. Nachar, PharmD, BCOP
Clinical Pharmacist Specialist - Ambulatory Hematology
University of Michigan Rogel Cancer Center
Adjunct Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan 

Marc H. Scheetz, PharmD, MSc, BCPS-AQID, FCCP
Professor of Pharmacy and Pharmacology; Director of Pharmacometrics Center of Excellence
Midwestern University
Downers Grove, Illinois
Infectious Diseases Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois 

Douglas Slain, PharmD, BCPS (AQ-ID), FCCP, FASHP*
Associate Professor and Infectious Diseases Clinical Specialist
West Virginia University School of Pharmacy
Morgantown, West Virginia 

Diana Solomon, PharmD, BCCCP
Critical Care Clinical Pharmacy Specialist
Cooper University HealthCare
Camden, New Jersey 

Trent G. Towne, PharmD, BCPS
Associate Professor of Pharmacy Practice
Manchester University College of Pharmacy
Clinical Pharmacy Specialist, Infectious Disease
Parkview Health System
Fort Wayne, Indiana
 

Kristin Watson, PharmD, BCCP
Associate Professor
University of Maryland School of Pharmacy
Baltimore, Maryland 

Jon Wietholter, PharmD, BCPS, FCCP
Clinical Associate Professor
West Virginia University School of Pharmacy
Internal Medicine Clinical Specialist
WVU Medicine Ruby Memorial Hospital
Morgantown, West Virginia

*Content Matter Experts

Anna M. Jackson, PharmD, BCPS
Tony Martin, PharmD, MBA

(Core Therapeutic Modules)

Shelbi Adams, PharmD, BCPS
Rachel  Malta, PharmD, BCPS
Shaun Randa, PharmD, BCPS
Hakeem Abayomi, BS, PharmD, BCPS, BCPPS, BCIDPS
Brian LeBaron, PharmD, BCPS, ACHIP, FAMIA
Casey Motto, PharmD, BCPS
John Healey, PharmD, BCPS
George Piasare, PharmD, BCPS
Courtney Robertson, PharmD, BCPS, CLC
Heather Petrie, PharmD, MBA, BCPS
Ian Andrus, PharmD, MBA, BCPS
Heather Schalk, PharmD, BCPS
Jon Bachna, PharmD, MBA, BCPS
Surafel Mulugeta, PharmD, MS, BCPS
Maisie So, PharmD, BCPS
Daphne Bernardin, PharmD
Michael Barton, PharmD, BCPS, BCGP
Mollie VanNatta, PharmD, BCPS, BCIDP
Eric Kinney, PharmD, BCPS
Sirisha Kandepi, PharmD, BCPS
Charles Maina, PharmD BCPS
Julie Asmus, PharmD, BCPS
Jessica Hagy, PharmD, BCPS
Bridger Singer, PharmD, BCPS, BCCCP
Leslie Wooten, PharmD, BCPS
Craigg Barr, PharmD, BCPS
Carly McKenzie, PharmD, BCPS
Joseph Rackson, PharmD, BCPS
Christine Williams, PharmD, BCPS, BCOP
Kristin Watson, PharmD, BCCP
Vikki Huggins, PharmD, BCPS
Seth Lilly, PharmD, BCPS
Ann Chung, PharmD, BCPS
Matthew Morrison, PharmD, BCPS
Adrienne O'Brien, PharmD, BCPS
Tara Breuer, RPh, BCPS, BCSCP
Melanie Crass, PharmD, BCPS
Tyler Vest, PharmD, MS, BCPS, BCSCP
Joseph Volk, PharmD, BCPS

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP.